Astra reports lower efficacy for COVID vaccine after criticism - BNN | Canada News Media
Connect with us

Business

Astra reports lower efficacy for COVID vaccine after criticism – BNN

Published

 on


AstraZeneca Plc reported a slightly lower efficacy rate for its COVID-19 vaccine after the results of an American clinical trial were criticized as outdated, raising further questions over the embattled shot and potentially delaying its approval in the U.S.

The vaccine was 76 per cent effective at protecting volunteers against the coronavirus, the U.K. drugmaker said in a statement on Thursday. That compares with an earlier estimate of 79%, which was based on data gathered through Feb. 17.

The latest twist created another layer of uncertainty for a product already facing dwindling support in Europe following months of confusion and missteps. Although the vaccine is still expected to play a crucial role in curbing the global pandemic as governments around the world have ordered millions of doses, the repeated blunders risk further eroding public confidence in the immunization.

“The difference between 76 per cent and 79 per cent is a rounding error, probably just a handful of cases,” said Paula Cannon, a professor of molecular microbiology and immunology at the University of Southern California’s Keck School of Medicine, where she leads a research team that studies viruses. “But it’s so important for us to be completely transparent and accurate because we are building public trust.”

The findings were based on 190 symptomatic cases that developed among the 32,449 volunteers who participated in the trial, which includes 49 cases that weren’t counted as part of the initial analysis. The company didn’t disclose how many of those infections occurred in the group that received the vaccine and how many in the one administered a placebo.

There are another 14 people with probable or possible infections, so the total number of cases may still change — which may cause the overall efficacy rate to adjust again.

Too Rushed?

Astra shares were little changed in London trading. The Cambridge, England-based company emphasized that the marginal changes in protection rate did not detract from the vaccine’s overall efficacy.

“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults,” said Mene Pangalos, the company’s executive vice president of BioPharmaceuticals research and development.

“We look forward to filing our regulatory submission for Emergency Use Authorization in the U.S. and preparing for the roll-out of millions of doses across America,” he said.

Some of Astra’s challenges reflect the unprecedented urgency of COVID-19 vaccine development, in which years-long processes have been compressed into several months.

“The problem with AstraZeneca is that they have had a couple of black eyes,” said Cannon. “I don’t think it’s malicious, it just reflects trying to get a vaccine out in the middle of a pandemic.”

Older Patients

In an unusual move earlier this week, a group of experts working with the company on the safety of its U.S. clinical trial contacted government agencies late on Monday to express concern about data that AstraZeneca made public just hours earlier. The company responded by saying it would soon release fresh estimates.

The vaccine developed with the University of Oxford was 100% effective at preventing severe disease and hospitalizations.

Older volunteers got the most benefit from the shot, with 85% of those aged 65 and over protected against symptomatic COVID. That finding is particularly important as it shows the vaccine benefits those most at risk from the virus, said Paul Griffin, director of infectious diseases at Mater Health Services and associate professor of medicine at the University of Queensland in Brisbane.

The U.S. trial data was seen as important because earlier research conducted in the U.K. and Brazil sowed confusion by producing two different efficacy readings. Plus, those tests failed to include enough elderly people to establish efficacy for that crucial patient group.

“Getting that message out to the community has been challenging, when other vaccines have had a much more simple message,” Griffin said. “Having a lot more complex one — with lots of different facets being released at different times — also has confused people. It has made some people apprehensive.”

–With assistance from Dong Lyu.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version